A jury in St. Louis rejected claims by three plaintiffs against Bayer that they linked cancer to the use of the herbicide Roundup. This is an important victory for the company in a decades-long legal battle over the drug, but the dispute over potential liability is far from over. The ruling was the first of its kind since the US Supreme Court ruled that it limited the ability to sue for the lack of cancer risk warnings on labels. This changes the legal terms of some of the proceedings, although in itself it does not mean an automatic end to all claims brought. The financial scale of the conflict remains enormous. Bayer has already spent more than $11 billion to settle similar lawsuits, and about 65,000 cases are still pending. Winning a three-plaintiff case reduces the pressure on a particular dispute, but the company continues to bear the risk of legal fees and payments for thousands of remaining cases. The outcome of a single trial does not decide the fate of the rest of the lawsuits. ECONOMY